Edition:
United States

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

5,585JPY
17 May 2019
Change (% chg)

¥124 (+2.27%)
Prev Close
¥5,461
Open
¥5,582
Day's High
¥5,598
Day's Low
¥5,480
Volume
1,422,800
Avg. Vol
2,042,180
52-wk High
¥5,820
52-wk Low
¥3,277

Select another date:

Tue, May 14 2019

FDA advisory panel votes against Daiichi Sankyo's blood cancer treatment

Independent experts on an advisory panel to the U.S. Food and Drug Administration on Tuesday voted against Daiichi Sankyo Co Ltd's treatment for adults with a type of acute myeloid leukemia.

UPDATE 1-FDA advisory panel votes against Daiichi Sankyo's blood cancer treatment

May 14 Independent experts on an advisory panel to the U.S. Food and Drug Administration on Tuesday voted against Daiichi Sankyo Co Ltd's treatment for adults with a type of acute myeloid leukemia.

FDA advisory panel votes against Daiichi Sankyo's cancer treatment

May 14 Independent experts on an FDA advisory panel on Tuesday voted against Daiichi Sankyo Co Ltd's treatment for adults with a type of acute myeloid leukemia.

AstraZeneca-Daiichi breast cancer treatment shows promise in latest study

An experimental breast cancer drug being developed by British drugmaker AstraZeneca and Japan's Daiichi Sankyo's met its main goal in a mid-stage study, bolstering their position in a highly competitive oncology market.

AstraZeneca-Daiichi Sankyo breast cancer drug shows promise

May 8 British drugmaker AstraZeneca and Japan's Daiichi Sankyo said on Wednesday their experimental treatment for breast cancer met its key goal in a mid-stage study, bolstering their defences in a highly competitive oncology market.

AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal

AstraZeneca Plc will pay up to $6.9 billion to work with Daiichi Sankyo Co Ltd on a hotly-tipped experimental treatment for breast cancer, in a direct challenge to the world's biggest cancer drug maker Roche.

UPDATE 5-AstraZeneca pays up to $6.9 bln in Daiichi Sankyo cancer deal

* Astra stock slides, deal part-funded by share issue (Releads, adds details on rivalry, analyst comments)

Nikkei up on U.S.-China trade talk optimism; Daiichi Sankyo jumps

TOKYO, March 29 Japan's Nikkei rose on Friday on optimism about the latest round of U.S.-China trade talks, with cyclical sectors such as shipping and machinery advancing on the last day of the Japanese fiscal year.

AstraZeneca and Daiichi Sankyo to jointly develop cancer drug

March 28 British drugmaker AstraZeneca Plc said late on Thursday it entered into a collaboration deal with Daiichi Sankyo Co Ltd of Japan to develop trastuzumab deruxtecan, a proprietary antibody-drug conjugate for cancer treatment.

Japan's Daiichi Sankyo explores OTC drugs business sale, hires JPMorgan -sources

TOKYO Japan's Daiichi Sankyo Co is exploring the sale of its over-the-counter drugs (OTC) business and has hired JPMorgan to advise on the potential deal, several people with knowledge of the matter told Reuters.

Select another date: